Drugs Containing Excipient (Inactive Ingredient) CETALKONIUM CHLORIDE

« Back to Dashboard

Branded drugs containing CETALKONIUM CHLORIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	CETALKONIUM CHLORIDE
Harrow Eye LLC	VERKAZIA	cyclosporine	82667-014	CETALKONIUM CHLORIDE

Generic drugs containing CETALKONIUM CHLORIDE excipient

Company	Ingredient	NDC	Excipient
Santen Incorporated	cyclosporine	65086-001	CETALKONIUM CHLORIDE
Harrow Eye LLC	cyclosporine	82667-014	CETALKONIUM CHLORIDE

Cetalkonium Chloride Market Dynamics and Financial Trajectory

Last updated: October 29, 2026

Cetalkonium chloride is a specialty cationic excipient used mainly as a surfactant, emulsifier, preservative, and antimicrobial agent. Its commercial value is concentrated in ophthalmic emulsions, topical products, oral-care formulations, cosmetics, and selected pharmaceutical delivery systems. The compound is inexpensive relative to finished medicines, but pharmaceutical-grade supply can command premiums because of impurity control, microbial specifications, batch consistency, documentation, and regulatory qualification.

No reliable public source reports a standalone global revenue figure for cetalkonium chloride. Market value is embedded in broader categories such as pharmaceutical excipients, quaternary ammonium compounds, ophthalmic products, surfactants, and personal-care ingredients. The financial trajectory is therefore best assessed through end-use demand, supplier economics, regulatory barriers, and the growth of products that require cetalkonium chloride in their formulation.

What is cetalkonium chloride and how is it used?

Cetalkonium chloride is a quaternary ammonium compound identified by CAS No. 122-18-9. It is also known as benzyl dimethyl hexadecyl ammonium chloride or hexadecylbenzyldimethylammonium chloride. The substance has cationic surface activity and antimicrobial properties.

In pharmaceutical formulations, cetalkonium chloride can perform several functions:

Function	Formulation role	Commercial relevance
Surfactant	Reduces interfacial tension and supports dispersion	Important in emulsions and suspensions
Emulsifier	Stabilizes oil-in-water systems	Relevant to ophthalmic emulsions and creams
Preservative or antimicrobial	Limits microbial growth	Useful at low concentrations, subject to tolerability
Wetting agent	Improves distribution of active ingredients	Supports topical and ocular delivery
Charge modifier	Interacts with anionic materials and biological surfaces	Can affect residence time and formulation behavior

The compound is not generally purchased by patients as an active pharmaceutical ingredient. Its value depends on the formulation performance of the finished product.

Cetalkonium chloride appears in regulatory and formulation databases as an excipient or inactive ingredient in drug products. The U.S. Food and Drug Administration’s Inactive Ingredient Database is the principal public reference for historical inactive-ingredient use in approved medicines, although database entries must be interpreted by route, dosage form, and maximum potency rather than as blanket approval for every formulation (U.S. Food and Drug Administration [FDA], n.d.-a).

Which pharmaceutical products use cetalkonium chloride?

The strongest pharmaceutical association is with ophthalmic emulsions. Cetalkonium chloride is used in products designed to deliver poorly water-soluble actives or to stabilize lipid-containing ocular formulations.

Ophthalmic emulsions

Cetalkonium chloride is present in certain cyclosporine ophthalmic emulsions and dry-eye products. In the European Union, Ikervis, a cyclosporine ophthalmic emulsion marketed by Santen Pharmaceutical, lists cetalkonium chloride among its excipients. The product is authorized for severe keratitis in adult patients with dry eye disease that has not improved with artificial tears (European Medicines Agency [EMA], 2015).

The excipient is commercially relevant because ophthalmic emulsions require tight control of:

• Particle and droplet size
• Sterility
• Preservative performance
• Ocular tolerability
• Container compatibility
• Physical stability
• Dose uniformity
• Extractables and leachables

A small quantity of cetalkonium chloride can therefore support a high-value finished product. The excipient itself remains a low-cost input, but supplier qualification can become difficult once it is embedded in a validated sterile formulation.

Topical and dermatological products

Cetalkonium chloride may be used in creams, lotions, gels, and antiseptic formulations as a cationic surfactant or antimicrobial agent. The opportunity is broader than ophthalmics, but competition is also greater because formulators can often substitute other quaternary ammonium compounds, cationic surfactants, phenoxyethanol, parabens, organic acids, or formulation-specific preservation systems.

Oral-care and consumer products

The compound has applications in oral-care and personal-care formulations, subject to jurisdiction-specific restrictions and concentration limits. These markets can provide volume diversification, but they are more price-sensitive than regulated ophthalmic products.

What drives demand for cetalkonium chloride?

Demand is linked to finished-product volume rather than to independent clinical demand for cetalkonium chloride. The main growth drivers are:

1. Expansion of dry-eye treatment and ophthalmic emulsions.
2. Greater use of lipid-based and emulsion-based delivery systems.
3. Outsourcing of formulation and sterile manufacturing.
4. Demand for multifunctional excipients that combine surfactant and antimicrobial properties.
5. Growth in topical and cosmeceutical products.
6. Increased use of pharmaceutical-grade materials with stronger traceability.

Dry-eye disease is the most commercially relevant pharmaceutical demand pool. Ageing populations, screen exposure, contact-lens use, meibomian-gland dysfunction, and greater diagnosis support continued demand for ocular lubricants and prescription anti-inflammatory therapies. Cetalkonium chloride does not benefit from every dry-eye product because many products use alternative emulsifiers or preservative-free formats.

The shift toward preservative-free ophthalmic products is a mixed factor. It can reduce demand for compounds used primarily for antimicrobial preservation. It can also increase demand for excipients that stabilize emulsions without relying on traditional multidose preservatives. The commercial effect depends on the specific formulation function of cetalkonium chloride.

How large is the cetalkonium chloride market?

A standalone market estimate cannot be validated from public regulatory filings because manufacturers generally do not disclose cetalkonium chloride revenue separately. Public market reports typically group it with broader categories, including:

• Pharmaceutical excipients
• Specialty surfactants
• Quaternary ammonium compounds
• Ophthalmic formulation ingredients
• Cosmetic preservatives
• Antimicrobial additives

Reported market figures from those categories are not interchangeable. A pharmaceutical excipient market estimate includes many materials that have no relationship to cetalkonium chloride. A quaternary ammonium compound estimate includes industrial disinfectants and fabric-care chemicals. Neither provides a defensible cetalkonium chloride revenue figure.

The most credible commercial conclusion is that cetalkonium chloride is a niche specialty excipient with low absolute volume and higher qualification value in pharmaceutical applications.

What is the financial trajectory for cetalkonium chloride?

The financial trajectory is likely to be stable-to-growing in value, with modest volume growth and higher pricing for pharmaceutical-grade material. Revenue performance should be separated into three segments.

Segment	Volume outlook	Pricing outlook	Margin profile
Pharmaceutical-grade excipient	Modest growth	Stable to firm	Higher because of qualification and documentation
Ophthalmic formulation supply	Selective growth	Premium pricing possible	Attractive when linked to validated products
Industrial, cosmetic, and oral-care grades	Mature or cyclical	Competitive	Lower margins and greater substitution risk

The largest financial upside is not likely to come from a major increase in kilograms sold. It is more likely to come from:

• Qualification in additional sterile products
• Multi-year supply agreements
• Higher-grade documentation
• Regulatory support packages
• Low-bioburden or controlled-microbial grades
• Dual-region manufacturing
• Technical services for emulsion development
• Supply into products with long commercial lifecycles

A supplier that sells only commodity-grade cetalkonium chloride will face pricing pressure. A supplier that provides validated pharmaceutical-grade material, change-control support, audit packages, and reliable global supply can defend higher margins.

Cost structure

The material is produced from quaternary ammonium chemistry involving long-chain alkyl and benzyl-containing inputs. Cost exposure may include:

• Fatty-chain feedstocks
• Benzyl chloride or related intermediates
• Energy and utilities
• Solvent recovery
• Waste treatment
• Analytical testing
• Packaging and transport
• Regulatory compliance
• Batch-release documentation

Raw-material volatility is likely to have a greater impact on lower-volume grades because production runs are smaller and fixed quality costs are spread over fewer units. Packaging and logistics are also relevant because cationic surfactants may require controlled handling and compatible containers.

Which companies supply or compete with cetalkonium chloride?

The supplier landscape is fragmented. Cetalkonium chloride can be sourced from specialty chemical producers, pharmaceutical excipient manufacturers, and regional chemical distributors. Public disclosures do not consistently identify supplier market shares.

Competition comes from two sources:

Direct suppliers

Direct suppliers compete on:

• Assay and impurity profile
• Batch size
• Country of manufacture
• GMP or quality-system coverage
• Regulatory support
• Lead time
• Minimum order quantity
• Supply continuity
• Price

The most important commercial distinction is often not chemical identity but grade and documentation. A cosmetic-grade product may not be acceptable for an ophthalmic product without additional qualification.

Substitute excipients

Formulators can consider alternative cationic surfactants, nonionic surfactants, phospholipids, poloxamers, polysorbates, tyloxapol, lecithin derivatives, benzalkonium chloride, and preservative-free delivery systems. Substitution depends on ocular tolerability, compatibility with the active ingredient, emulsion stability, sterilization method, and regulatory precedent.

Benzalkonium chloride is a particularly relevant comparator in preservative applications. It has extensive historical use but can cause ocular-surface toxicity with repeated exposure, which has encouraged preservative-free products and alternative preservation strategies. Cetalkonium chloride may be selected when the formulation requires a different balance of emulsification, antimicrobial activity, and ocular tolerability.

What regulatory status applies to cetalkonium chloride?

Cetalkonium chloride does not have one universal regulatory status. Its acceptability depends on:

• Route of administration
• Dosage form
• Concentration
• Function in the product
• Product-specific safety data
• Country or regional requirements
• Precedent in approved products

In the United States, an inactive-ingredient listing indicates historical use in an approved drug product. It does not create independent authorization for all uses or concentrations. FDA review remains product-specific (FDA, n.d.-a).

In the European Union, excipient safety is assessed within the marketing authorization framework. The EMA’s excipient guidance requires applicants to provide appropriate information on excipients, including safety and justification where relevant (EMA, 2018).

For ophthalmic use, regulatory scrutiny is higher because excipient-related risks can include irritation, epithelial toxicity, inflammation, adsorption to packaging, and effects on the tear film. The same material may be acceptable in a topical cream but require substantially more evidence in a sterile ocular product.

What patents protect cetalkonium chloride formulations?

The chemical compound itself is old and is unlikely to provide a meaningful new-compound patent barrier in modern commercial markets. Competitive protection is more likely to arise from:

• Specific ophthalmic emulsions
• Particle-size distributions
• Concentration ranges
• Combination systems with cyclosporine or other actives
• Container and delivery systems
• Sterilization processes
• Manufacturing methods
• Stability improvements
• Preservative-free multidose packaging

Product-level patents may protect a finished drug formulation that includes cetalkonium chloride, but those patents do not create exclusivity over the excipient itself.

How strong is the patent estate?

The excipient-level patent estate is likely weak because cetalkonium chloride is an established chemical entity. The formulation-level estate can be stronger when the excipient is integrated into a specific delivery technology.

Patent strength depends on claim scope and design-around risk. A patent claiming a narrow concentration range may be vulnerable to reformulation outside that range. A patent covering a defined emulsion structure, particle-size profile, or manufacturing process may be more difficult to avoid if the product requires those technical characteristics.

Public patent databases should be reviewed at the product level rather than under cetalkonium chloride alone. Searching only the chemical name can miss patents that claim the formulation without naming the excipient in the title or abstract.

When does cetalkonium chloride lose exclusivity?

Cetalkonium chloride does not have a single exclusivity date comparable to a branded drug. The underlying chemical is established, and manufacturers can generally enter subject to applicable chemical, quality, safety, and regulatory requirements.

The relevant exclusivity dates belong to finished products that contain cetalkonium chloride. These may include:

Protection type	Applies to	Commercial effect
Composition patent	New chemical entity or novel active	Usually not relevant to cetalkonium chloride
Formulation patent	Emulsion, suspension, or dosage form	Can delay product-level competition
Method-of-use patent	Treatment indication	May affect generic labeling
Process patent	Manufacturing or sterilization method	Usually design-around risk exists
Regulatory exclusivity	Approved finished drug	Applies to the drug product, not the excipient
Trade secret	Manufacturing parameters or know-how	Can create practical barriers without formal exclusivity

Are there Paragraph IV challenges or biosimilar risks?

Paragraph IV litigation applies to abbreviated new drug applications that challenge listed patents for branded drug products. It does not apply to cetalkonium chloride as a standalone excipient.

A generic manufacturer using cetalkonium chloride could face Paragraph IV litigation if the reference drug has Orange Book-listed patents covering the finished formulation, method of use, or delivery system. The challenge would concern the branded drug, not ownership of cetalkonium chloride.

Biosimilar risk is not relevant to the excipient because cetalkonium chloride is a small-molecule chemical and is not a biologic. Biosimilar competition may affect a biologic product that uses the excipient, but there is no biosimilar pathway for cetalkonium chloride itself.

What is the Orange Book status of cetalkonium chloride?

Cetalkonium chloride is not generally listed in the Orange Book as an independently marketed active drug with its own reference product exclusivity. The Orange Book records approved drug products and associated patents, exclusivity, and therapeutic-equivalence information. An excipient may appear in the inactive-ingredient section of a product but does not receive a separate Orange Book patent listing solely because it is present in the formulation (FDA, n.d.-b).

For commercial diligence, the correct process is to identify each branded drug containing cetalkonium chloride, review its Orange Book entry, identify listed patents, and assess the expiry and litigation status of those product-level rights.

What manufacturing and intellectual-property barriers exist?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Pharmaceutical customers may require:

• Validated analytical methods
• Defined assay and impurity limits
• Microbial and endotoxin controls
• Residual-solvent testing
• Heavy-metal and elemental-impurity controls
• Batch-to-batch consistency
• Change-control procedures
• Auditable quality systems
• Stability data
• Regulatory support for customer submissions

Ophthalmic applications add sterile-manufacturing and container-compatibility requirements at the finished-product level. The excipient supplier may not need to manufacture sterile material, but it must provide consistent material suitable for the customer’s sterilization and formulation process.

Intellectual-property barriers

The main IP barriers are likely to involve:

• Formulation know-how
• Emulsion processing
• Mixing order
• Homogenization conditions
• Droplet-size control
• Packaging design
• Preservative systems
• Combination therapy
• Manufacturing parameters

These barriers can limit substitution even when the chemical itself is available from multiple sources.

What generic launch scenarios affect cetalkonium chloride demand?

Three launch scenarios are commercially relevant.

Scenario one: Branded ophthalmic product remains protected

Demand remains tied to the originator’s formulation and supply chain. Volume grows with the branded product, while supplier switching is limited by qualification requirements.

Scenario two: Generic or authorized-generic entry

Cetalkonium chloride demand may increase if multiple manufacturers use the same or similar excipient system. Unit prices can decline as buyers gain leverage, but total volume may rise.

Scenario three: Formulation redesign

A generic or competing product may use a different surfactant, preservative-free container, or alternative emulsion system. This creates substitution risk even if the underlying ophthalmic market expands.

The strongest demand outcome occurs when market growth produces more finished products without eliminating cetalkonium chloride from their formulations.

How does cetalkonium chloride compare with benzalkonium chloride?

Factor	Cetalkonium chloride	Benzalkonium chloride
Primary role	Surfactant, emulsifier, antimicrobial excipient	Preservative, antimicrobial agent, surfactant
Ophthalmic relevance	Emulsions and selected ocular products	Extensive historical preservative use
Ocular-tolerability concern	Product- and concentration-dependent	Repeated exposure can damage ocular surface
Substitution risk	Moderate to high	Moderate, driven by preservative-free trends
Patent value	Mainly formulation-level	Mainly formulation and delivery-system level
Commercial positioning	Specialty excipient	Larger and more established preservative market

Cetalkonium chloride is more dependent on formulation-specific performance. Benzalkonium chloride has broader historical use but faces stronger pressure from preservative-free ophthalmic products.

Key Takeaways

• Cetalkonium chloride is a niche pharmaceutical excipient with applications in ophthalmic emulsions, topical products, oral care, and cosmetics.
• Its strongest pharmaceutical value is linked to sterile ocular formulations and products containing poorly water-soluble active ingredients.
• No defensible standalone global revenue figure is publicly available because suppliers report cetalkonium chloride within broader chemical or excipient categories.
• The likely financial trajectory is stable to moderately positive, with value growth driven by qualification, regulatory support, and specialty-grade supply rather than high-volume expansion.
• The chemical itself has limited exclusivity value. Formulation patents, manufacturing processes, container systems, and product-level regulatory rights create the relevant barriers.
• Paragraph IV challenges and Orange Book rights apply to finished drug products, not to cetalkonium chloride as an excipient.
• Biosimilar competition is not directly relevant.
• The largest risks are substitution by alternative surfactants, preservative-free delivery systems, supplier consolidation, raw-material volatility, and loss of a key ophthalmic customer.
• The strongest supplier position combines pharmaceutical-grade manufacturing, audit-ready documentation, regional supply redundancy, and technical support for emulsion development.

FAQs

Is cetalkonium chloride an active pharmaceutical ingredient?

Usually no. It is generally used as an inactive excipient, surfactant, emulsifier, preservative, or antimicrobial component. Its regulatory status depends on the finished product and route of administration.

Is cetalkonium chloride used in dry-eye medicines?

Yes. It is used in selected ophthalmic emulsions, including products containing cyclosporine. Its role can include emulsion stabilization and surface-active functionality.

Can cetalkonium chloride be replaced by benzalkonium chloride?

Sometimes, but substitution is formulation-specific. The two compounds differ in physicochemical behavior, ocular tolerability, preservation performance, and regulatory precedent.

Does cetalkonium chloride have standalone drug patents?

The compound is an established chemical and is unlikely to provide a meaningful modern composition-of-matter barrier. Patent protection is more likely to cover a finished formulation, delivery system, manufacturing process, or method of use.

Is cetalkonium chloride exposed to generic competition?

Indirectly. Generic competition can affect demand when generic manufacturers copy or redesign a finished product containing cetalkonium chloride. The excipient itself is not the subject of an ANDA Paragraph IV challenge.

References

European Medicines Agency. (2015). Ikervis: EPAR - product information. https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis

European Medicines Agency. (2018). Excipients in the labelling and package leaflet of medicinal products for human use. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/excipients-labelling

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm